Atossa Therapeutics (ATOS) Change in Account Payables (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Change in Account Payables of -$1.7 million for Q1 2026, down 454.73% year-over-year from $486000.0 in Q1 2025, and down 326.54% quarter-over-quarter from $761000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Change in Account Payables (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Change in Account Payables for 16 consecutive years, with -$1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 454.73% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at $1.4 million (up 2260.0% YoY), while the FY2025 annual figure was $3.6 million, up 2945.67% from the prior year.
- Change in Account Payables slipped to -$1.7 million in Q1 2026 per ATOS's latest filing, from $761000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.5 million in Q3 2025 and bottomed at -$1.7 million in Q1 2026.
- Historically, Change in Account Payables has averaged $50117.6 across 5 years, with a median of $88000.0 in 2023.
- Annual changes were most pronounced in 2023 — Change in Account Payables tumbled 1157.02% — and 2025, when it surged 585.63%.
- Atossa Therapeutics' Change in Account Payables stood at $1.3 million in 2022, then slumped by 93.29% to $88000.0 in 2023, then sank by 1102.27% to -$882000.0 in 2024, then soared by 186.28% to $761000.0 in 2025, then sank by 326.54% to -$1.7 million in 2026.
- Business Quant data shows ATOS's Change in Account Payables at -$1.7 million in Q1 2026, $761000.0 in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | -593,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -593,000.00 |
| Jun 30, 2026 | -593,000.00 |
| Mar 31, 2026 | -1.72 Mn |
| Mar 31, 2026 | -1.72 Mn |
| Dec 31, 2025 | 761,000.00 |
| Dec 31, 2025 | 761,000.00 |
| Sep 30, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 845,000.00 |
| Jun 30, 2025 | 845,000.00 |
| Mar 31, 2025 | 486,000.00 |
| Mar 31, 2025 | 486,000.00 |
| Dec 31, 2024 | -882,000.00 |
| Dec 31, 2024 | -882,000.00 |
| Sep 30, 2024 | 505,000.00 |
| Sep 30, 2024 | 505,000.00 |
| Jun 30, 2024 | -174,000.00 |
| Jun 30, 2024 | -174,000.00 |
| Mar 31, 2024 | 424,000.00 |
| Mar 31, 2024 | 424,000.00 |